BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 2968259)

  • 21. Comparative study of renal scintigraphy with 99Tcm-mercaptoacetyltriglycine and 123I-orthoiodohippurate.
    Itoh K; Tsukamoto E; Kakizaki H; Nonomura K; Furudate M
    Nucl Med Commun; 1993 Aug; 14(8):644-52. PubMed ID: 8371889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 99mTc-MAG3, a new renal imaging agent: preliminary results in patients.
    Taylor A; Eshima D; Alazraki N
    Eur J Nucl Med; 1987; 12(10):510-4. PubMed ID: 2952506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reproducibility of single-sample clearance of 99mTc-mercaptoacetyltriglycine and 131I-orthoiodohippurate.
    Russell CD; Dubovsky EV
    J Nucl Med; 1999 Jul; 40(7):1122-4. PubMed ID: 10405130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Usefulness of renal dynamic function study with 99mTc-MAG3 (mercaptoacetylglycylglycylglycine)].
    Shirakawa S; Tamaki N; Torizuka T; Fujita T; Yano S; Tsuchimochi S; Yonekura Y; Konishi J; Terai A
    Kaku Igaku; 1994 Aug; 31(8):977-83. PubMed ID: 7933686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacokinetics of 99mTc-MAG3 and 131I-OIH: comparative study based on 2 compartment model analysis].
    Shuke N; Takashio T; Sato J; Ishikawa Y; Saito Y; Yamamoto W; Aburano T; Mizunaga M; Kaneko S; Yachiku S; Ogawa Y; Kikuchi K; Sasajima T; Kubo Y
    Kaku Igaku; 1996 May; 33(5):513-20. PubMed ID: 8699619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 99mTc-MAEC complexes: new renal radiopharmaceuticals combining characteristics of (99m)Tc-MAG3 and (99m)Tc-EC.
    Taylor AT; Lipowska M; Hansen L; Malveaux E; Marzilli LG
    J Nucl Med; 2004 May; 45(5):885-91. PubMed ID: 15136640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The estimation of effective renal plasma flow (ERPF) based on two compartment analysis using 99mTc-mercaptoacetyltriglycine (99mTc-MAG3)].
    Ha-Kawa SK; Suga Y; Satou H; Tanaka Y
    Kaku Igaku; 1994 Feb; 31(2):175-81. PubMed ID: 8121073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical assessment of 99mTc-MAG3 scintigraphy for impaired renal function].
    Sato M; Hirayama K; Ishikawa N; Takeda T; Wu J; Itai Y; Kobayashi M; Koyama A
    Kaku Igaku; 1994 Jan; 31(1):75-84. PubMed ID: 8309113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of renal function using 99mTc-MAG3: comparison with 123I-OIH and 99mTc-DTPA].
    Takayama T; Aburano T; Shuke N; Yokoyama K; Michigishi T; Sun BF; Tonami N; Hisada K; Takabatake T; Ohta H
    Kaku Igaku; 1993 Jul; 30(7):753-60. PubMed ID: 8377298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitation of renal function with technetium-99m MAG3.
    Russell CD; Thorstad BL; Yester MV; Stutzman M; Dubovsky EV
    J Nucl Med; 1988 Dec; 29(12):1931-3. PubMed ID: 2973517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Filtration fraction and its implications for radionuclide renography using diethylenetriaminepentaacetic acid and mercaptoacetyltriglycine.
    Gates GF
    Clin Nucl Med; 2004 Apr; 29(4):231-7. PubMed ID: 15096969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of renal transplant survival from early postoperative radioisotope studies.
    Russell CD; Yang H; Gaston RS; Hudson SL; Diethelm AG; Dubovsky EV
    J Nucl Med; 2000 Aug; 41(8):1332-6. PubMed ID: 10945523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of technetium-99m-MAG3 in humans.
    Bubeck B; Brandau W; Weber E; Kälble T; Parekh N; Georgi P
    J Nucl Med; 1990 Aug; 31(8):1285-93. PubMed ID: 2143528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 99mTc renal tubular function agents: current status.
    Eshima D; Fritzberg AR; Taylor A
    Semin Nucl Med; 1990 Jan; 20(1):28-40. PubMed ID: 2136959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Advantages of the new radiopharmaceutic agent, 99mTC-mercaptoacetyltriglycine (99mTc-MAG3), in the diagnosis of kidneydiseases. A comparative study with 131I-OIH, 99mTc-DTPA and 99mTc-DMSA].
    Lepej J; Marosová A; Kliment J; Buchanec J; Svitác J; Klisenbauer L
    Bratisl Lek Listy; 1992 May; 93(5):258-65. PubMed ID: 1327424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Technetium-99m-MAG3 versus iodine-123-OIH: renal clearance and distribution volume as measured by a constant infusion technique.
    Prenen JA; de Klerk JM; van het Schip AD; van Rijk PP
    J Nucl Med; 1991 Nov; 32(11):2057-60. PubMed ID: 1834812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of 99mTc-mercaptoacetyltriglycine and [131I]-o-iodohippurate elimination in perfused rat kidney.
    Trejtnar F; Laznicek M; Laznickova A
    Nucl Med Biol; 2003 Jan; 30(1):45-9. PubMed ID: 12493542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of renal function using 99mTc-MAG3 comparison with 131I-OIH by simultaneous dual energy peak acquisition method].
    Hashimoto T; Matsumoto K; Ishibashi R; Iwasaki R; Sanmiya T; Hashimoto J; Kunieda E; Nakamura K; Kubo A
    Kaku Igaku; 1995 Feb; 32(2):139-46. PubMed ID: 7715099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Technetium-99m MAG-3 clearances after captopril in experimental renovascular hypertension.
    Lee HB; Blaufox MD
    J Nucl Med; 1989 May; 30(5):666-71. PubMed ID: 2523959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Technetium-99m-EC and other potential new agents in renal nuclear medicine.
    Moran JK
    Semin Nucl Med; 1999 Apr; 29(2):91-101. PubMed ID: 10321823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.